Have a personal or library account? Click to login
Influence of Age of Onset on Huntington’s Disease Phenotype Cover

Influence of Age of Onset on Huntington’s Disease Phenotype

Tremor and Other Hyperkinetic Movements
Volume 10 (2020): Issue 0
By: Lauren Kwa,  Danielle Larson,  Chen Yeh and  Danny Bega  
Open Access
|Jul 2020

References

  1. 1Lee J-M, Ramos E, Lee J-H, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012; 78(10): 690–95. DOI: 10.1212/WNL.0b013e318249f683
    Back to article
  2. 2Myers RH. Huntington’s disease genetics. NeuroRx. 2004; 1(2): 255–62. DOI: 10.1602/neurorx.1.2.255
    Back to article
  3. 3Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nature Genetics. 1993; 4(4): 387. DOI: 10.1038/ng0893-387
    Back to article
  4. 4Ranganathan M, Race JA, Allain DC, et al. Presentation of Behavioral Symptoms Varies with Age of Disease Onset in Huntington Disease. HSG 2018: Unlocking HD. Houston, TX: Neurotherapeutics, 2018: 1168–214.
    Back to article
  5. 5Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington’s disease. Movement Disorders. 1995; 10(2): 211–14. DOI: 10.1002/mds.870100213
    Back to article
  6. 6Mahant N, McCusker E, Byth K, et al. Huntington’s disease: clinical correlates of disability and progression. Neurology. 2003; 61(8): 1085–92. DOI: 10.1212/01.WNL.0000086373.32347.16
    Back to article
  7. 7Access Data, Biosamples and Clinical Rater Training enroll-hd.org: CHDI Foundation, Inc.; 2020. Available from: https://www.enroll-hd.org/for-researchers/access-data/ accessed 5/25/20 2020.
    Back to article
  8. 8Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, et al. Data analytics from Enroll-HD, a global clinical research platform for Huntington’s disease. Movement Disorders Clinical Practice. 2017; 4(2): 212–24. DOI: 10.1002/mdc3.12388
    Back to article
  9. 9Squitieri F, Frati L, Ciarmiello A, et al. Juvenile Huntington’s disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mechanisms of ageing and development. 2006; 127(2): 208–12. DOI: 10.1016/j.mad.2005.09.012
    Back to article
  10. 10Quarrell O, O’Donovan KL, Bandmann O, et al. The prevalence of juvenile Huntington’s disease: a review of the literature and meta-analysis. 2012; 4. DOI: 10.1371/4f8606b742ef3
    Back to article
  11. 11Oosterloo M, Bijlsma EK, Van Kuijk SM, et al. Clinical and genetic characteristics of late-onset Huntington’s disease. 2019; 61: 101–05. DOI: 10.1016/j.parkreldis.2018.11.009
    Back to article
  12. 12Roos RAJ. Huntington’s disease: a clinical review. Ojord. 2010; 5(1): 40. DOI: 10.1186/1750-1172-5-40
    Back to article
  13. 13Koutsis G, Karadima G, Kladi A, et al. Late-onset Huntington’s disease: diagnostic and prognostic considerations. 2014; 20(7): 726–30. DOI: 10.1016/j.parkreldis.2014.03.017
    Back to article
  14. 14Cornejo-Olivas MR, Inca-Martinez MA, Espinoza-Huertas K, et al. Clinical and molecular features of late onset Huntington disease in a Peruvian cohort. 2015; 4(1): 99–105. DOI: 10.3233/JHD-140119
    Back to article
  15. 15Chaganti SS, McCusker EA, Loy CT. What do we know about late onset Huntington’s disease? JJoHsd. 2017; 6(2): 95–103. DOI: 10.3233/JHD-170247
    Back to article
  16. 16Wild E, Tabrizi S. Premanifest and early Huntington’s disease. Huntington’s Disease (Oxford Monographs on Medical Genetics). Oxford University Press; 2014. DOI: 10.1093/med/9780199929146.003.0005
    Back to article
  17. 17Shoulson I, Fahn S. Huntington disease. Clinical care and evaluation. 1979; 29(1): 1–1. DOI: 10.1212/WNL.29.1.1
    Back to article
  18. 18Novak MJ, Tabrizi SJ. Huntington’s disease: clinical presentation and treatment. International review of neurobiology: Elsevier. 2011: 297–323. DOI: 10.1016/B978-0-12-381328-2.00013-4
    Back to article
  19. 19Winder JY, Achterberg WP, Marinus J, et al. Assessment Scales for Patients with Advanced Huntington’s Disease: Comparison of the UHDRS and UHDRS-FAP. 2018; 5(5): 527–33. DOI: 10.1002/mdc3.12646
    Back to article
  20. 20Rishi P, Rishi E, Maitray A, et al. Hospital anxiety and depression scale assessment of 100 patients before and after using low vision care: A prospective study in a tertiary eye-care setting. 2017; 65(11): 1203. DOI: 10.4103/ijo.IJO_436_17
    Back to article
  21. 21Snaith R, Constantopoulos A, Jardine M, et al. A clinical scale for the self-assessment of irritability. 1978; 132(2): 164–71. DOI: 10.1192/bjp.132.2.164
    Back to article
  22. 22Quarrell OW, Nance MA, Nopoulos P, et al. Managing juvenile Huntington’s disease. 2013; 3(3): 267–76. DOI: 10.2217/nmt.13.18
    Back to article
  23. 23Puhan MA, Frey M, Büchi S, et al. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. 2008; 6(1): 46. DOI: 10.1186/1477-7525-6-46
    Back to article
  24. 24Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington’s disease. Archives of Neurology. 1996; 53(6): 493–97. DOI: 10.1001/archneur.1996.00550060035012
    Back to article
  25. 25Lewit-Mendes MF, Lowe GC, Lewis S, et al. Young People Living at Risk of Huntington’s Disease: The Lived Experience. Journal of Huntington’s disease. 2018(Preprint): 1–12.
    Back to article
  26. 26Bužgová R, Kozáková R. Informing patients with progressive neurological disease of their health status, and their adaptation to the disease. BMC neurology. 2019; 19(1): 250. DOI: 10.1186/s12883-019-1488-y
    Back to article
  27. 27Anderson KE, Griffin J, Kinel A, et al. Quality of Care for Huntington’s Disease in the United States: Findings from a National Survey of Patients and Caregivers. Journal of Huntington’s disease. 2019(Preprint): 1–11.
    Back to article
  28. 28Vamos M, Hambridge J, Edwards M, et al. The impact of Huntington’s disease on family life. Psychosomatics. 2007; 48(5): 400–04. DOI: 10.1176/appi.psy.48.5.400
    Back to article
  29. 29Aubeeluck A, Moskowitz CB. Huntington’s disease. Part 3: family aspects of HD. British Journal of Nursing. 2008; 17(5): 328–31. DOI: 10.12968/bjon.2008.17.5.28830
    Back to article
  30. 30Kringlen G, Kinsley L, Aufox S, et al. The Impact of Family History on the Clinical Features of Huntington’s Disease. Journal of Huntington’s disease. 2017; 6(4): 327–35. DOI: 10.3233/JHD-170256
    Back to article
  31. 31Carlozzi NE, Tulsky DS. Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. Journal of health psychology. 2013; 18(2): 212–25. DOI: 10.1177/1359105312438109
    Back to article
  32. 32Watkins K, Purks J, Kumar A, et al. Huntington’s Disease and Employment: The Relative Contributions of Cognitive and Motor Decline to the Decision to Leave Work. Journal of Huntington’s disease. 2018(Preprint): 1–12.
    Back to article
  33. 33Whitley E, Popham F. Leaving the labour market later in life: how does it impact on mechanisms for health? Occup Environ Med. 2017; 74(12): 877–86. DOI: 10.1136/oemed-2016-104258
    Back to article
  34. 34DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. The Lancet Neurology. 2003; 2(1): 15–21. DOI: 10.1016/S1474-4422(03)00262-X
    Back to article
  35. 35Radák Z, Kaneko T, Tahara S, et al. Regular exercise improves cognitive function and decreases oxidative damage in rat brain. Neurochemistry international. 2001; 38(1): 17–23. DOI: 10.1016/S0197-0186(00)00063-2
    Back to article
  36. 36Bonner-Jackson A, Long JD, Westervelt H, et al. Cognitive reserve and brain reserve in prodromal Huntington’s disease. Journal of the International Neuropsychological Society. 2013; 19(7): 739–50. DOI: 10.1017/S1355617713000507
    Back to article
  37. 37Gómez-Tortosa E, del Barrio A, Ruiz PJG, et al. Severity of cognitive impairment in juvenile and late-onset Huntington disease. Archives of neurology. 1998; 55(6): 835–43. DOI: 10.1001/archneur.55.6.835
    Back to article
  38. 38Starkstein SE, Brandt J, Bylsma F, et al. Neuropsychological correlates of brain atrophy in Huntington’s disease: a magnetic resonance imaging study. Neuroradiology. 1992; 34(6): 487–89. DOI: 10.1007/BF00598956
    Back to article
  39. 39Ruocco H, Lopes-Cendes I, Li L, et al. Striatal and extrastriatal atrophy in Huntington’s disease and its relationship with length of the CAG repeat. Brazilian journal of medical and biological research. 2006; 39(8): 1129–36. DOI: 10.1590/S0100-879X2006000800016
    Back to article
  40. 40Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease. Nature genetics. 1993; 4(4): 393. DOI: 10.1038/ng0893-393
    Back to article
  41. 41Ruocco HH, Bonilha L, Li LM, et al. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. Journal of Neurology, Neurosurgery & Psychiatry. 2008; 79(2): 130–35. DOI: 10.1136/jnnp.2007.116244
    Back to article
  42. 42Fritz NE, Rao AK, Kegelmeyer D, et al. Physical therapy and exercise interventions in Huntington’s disease: a mixed methods systematic review. Journal of Huntington’s disease. 2017; 6(3): 217–35. DOI: 10.3233/JHD-170260
    Back to article
DOI: https://doi.org/10.5334/tohm.536 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Jun 4, 2020
Accepted on: Jun 26, 2020
Published on: Jul 9, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Huntington Disease (HD),
Enroll-HD,
phenotype,
UHDRS,
TFC

© 2020 Lauren Kwa, Danielle Larson, Chen Yeh, Danny Bega, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 10 (2020): Issue 0Next article